Analyst Price Targets — ANIP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:32 am | Vamil Divan | Guggenheim | $124.00 | $85.29 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim |
| October 9, 2025 1:23 pm | — | Truist Financial | $90.00 | $91.63 | TheFly | ANI Pharmaceuticals price target raised to $90 from $77 at Truist |
| September 17, 2025 2:17 pm | Brandon Folkes | H.C. Wainwright | $121.00 | $95.36 | TheFly | ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright |
| September 8, 2025 11:46 am | Vamil Divan | Guggenheim | $114.00 | $95.20 | TheFly | ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim |
| August 8, 2025 3:00 pm | David Amsellem | Piper Sandler | $94.00 | $81.13 | TheFly | ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler |
| March 5, 2025 1:58 pm | — | Guggenheim | $86.00 | $59.68 | TheFly | ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim |
| September 18, 2024 9:14 am | Gary Nachman | Raymond James | $83.00 | $61.23 | TheFly | ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James |
| September 11, 2024 6:06 am | Les Sulewski | Truist Financial | $60.00 | $55.48 | TheFly | ANI Pharmaceuticals downgraded to Hold from Buy at Truist |
| June 26, 2024 6:36 am | Oren Livnat | H.C. Wainwright | $94.00 | $65.49 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright |
| May 13, 2024 7:17 am | Oren Livnat | H.C. Wainwright | $87.00 | $68.06 | StreetInsider | ANI Pharmaceuticals (ANIP) PT Raised to $87 at H.C. Wainwright |
Latest News for ANIP
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. I see near-term risks from seasonally weaker Cortrophin sales due to insurance reverifications and delayed impact from the expanded gout sales force. Management reaffirmed 2026 guidance for $1.06-$1.12B revenue and up to $290M adjusted EBITDA, but execution and timing risks remain.
ANI Pharmaceuticals (NASDAQ: ANIP) reported fourth-quarter and full-year 2025 results highlighting record revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS, driven by growth in its rare disease and generics businesses. Management also reaffirmed 2026 guidance calling for more than $1 billion in revenue and continued expansion led by Cortrophin Gel. Record 2025 performance driven by
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares are down early Friday following the company's strong fourth-quarter report.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANIP.
U.S. House Trading
No House trades found for ANIP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.